Analyst Mathew Blackman from TD Cowen maintained a Buy rating on Intuitive Surgical and decreased the price target to $585.00 from $660.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mathew Blackman has given his Buy rating due to a combination of factors centered on Intuitive Surgical’s strong first‑quarter performance and improving utilization trends. The company delivered upside on key metrics such as procedures and system placements, with U.S. strength more than offsetting international challenges, and the newer DV5 platform is already driving meaningfully higher throughput versus prior generations, supporting sustainable procedure growth as it becomes a larger share of the installed base.
Blackman also notes that international headwinds in markets like China, Japan, and the U.K. are manageable, not worsening, and should gradually diminish as a percentage of total volume, while reimbursement and funding developments abroad may unlock additional upside over time. Competitive concerns and broader MedTech utilization worries appear overstated in light of current results, reinforcing his view that the company’s growth drivers and technology leadership provide more tailwinds than headwinds, justifying a Buy recommendation.
In another report released today, Piper Sandler also assigned a Buy rating to the stock with a $580.00 price target.